Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: New molecular insight into the mechanism of action

European Journal of Pharmacology

Volumn 658, Issue 2-3, 2011, Pages 57-64

  Martínez Serra, Jordi ^a,b   Maffiotte, Elena ^a   Martín, Javier ^a   Bex, Teresa ^a,b   Navarro Palou, María ^a,b   Ros, Teresa ^a   Plazas, Joana M ^a   Vögler, Oliver ^b   Gutiérrez, Antonio ^a   Amat, Juan Carlos ^a   Ramos, Rafael ^a   Saus, Carlos ^a   Ginés, Jordi ^a   Alemany, Regina ^b   Diaz, Matias ^a   Besalduch, Joan ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b UNIVERSITAT DE LES ILLES BALEARS   (Spain)

Author keywords

Caspase 8; Dexamethasone; Fas; Flip (L); Trabectedin; Yondelis

Indexed keywords

CASPASE 8; DEATH RECEPTOR; DEXAMETHASONE; FAS LIGAND; FLICE INHIBITORY PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; TRABECTEDIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG SENSITIZATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER PROTECTION; LIVER TOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS REGULATION; TREATMENT OUTCOME;

ANTIBODIES; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; DEXAMETHASONE; DIOXOLES; FAS LIGAND PROTEIN; HUMANS; LIVER; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; TETRAHYDROISOQUINOLINES;

EID: 79953773860     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.02.035     Document Type: Article

References (35)

1. Allavena, P., Signorelli, M., Chieppa, M., Erba, E., Bianchi, G., Marchesi, F., Olimpio, C.O., Bonardi, C., Garbi, A., Lissoni, A., de Braud, F., Jimeno, J., D'Incalci, M., 2005. Antiinflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res. 65, 2964-2971. (Pubitemid 40490102)
2. Beumer, J.H., Schellens, J.H., Beijnen, J.H., 2005. Hepatotoxicity and metabolism of trabectedin: a literature review. Pharmacol. Res. 51, 391-398.
3. Bian, X., Giordano, T.D., Lin, H.J., Solomon, G., Castle, V.P., Opipari Jr., A.W., 2004. Chemotherapy-induced apoptosis of S-type neuroblastoma cells requires caspase-9 and is augmented by CD95/Fas stimulation. J. Biol. Chem. 279, 4663-4669.
4. Boatright, K.M., Deis, C., Denault, J.B., Sutherlin, D.P., Salvesen, G.S., 2004. Activation of caspases-8 and -10 by FLIP(L). Biochem. J. 382, 651-657.
5. Chen, Y.X., Wang, Y., Fu, C.C., Diao, F., Song, L.N., Li, Z.B., Yang, R., Lu, J., Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells. Endocr. Relat. Cancer 17, 39-50.
6. Damia, G., Silvestri, S., Carrassa, L., Filiberti, L., Faircloth, G.T., Liberi, G., Foiani, M., D'Incalci, M., 2001. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int. J. Cancer 92, 583-588. (Pubitemid 32319434)
7. Donald, S., Verschoyle, R.D., Greaves, P., Gant, T.W., Colombo, T., Zaffaroni, M., Frapolli, R., Zucchetti, M., D'Incalci, M., Meco, D., Riccardi, R., Lopez-Lazaro, L., Jimeno, J., Gescher, A.J., 2003. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat. Cancer Res. 63, 5902-5908. (Pubitemid 37187491)
8. Erba, E., Bergamaschi, D., Bassano, L., Damia, G., Ronzoni, S., Faircloth, G.T., D'Incalci, M., 2001. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur. J. Cancer 37, 97-105. (Pubitemid 32119366)
9. Fayette, J., Coquard, I.R., Alberti, L., Boyle, H., Meeus, P., Decouvelaere, A.V., Thiesse, P., Sunyach, M.P., Ranchere, D., Blay, J.Y., 2006. ET-743: a novel agent with activity in soft-tissue sarcomas. Curr. Opin. Oncol. 18, 347-353.
10. Gajate, C., An, F., Mollinedo, F., 2002. Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis. J. Biol. Chem. 277, 41580-41589.
11. Garcia, S., Liz, M., Gomez-Reino, J.J., Conde, C., Akt activity protects rheumatoid synovial fibroblasts from Fas-induced apoptosis by inhibition of Bid cleavage. Arthritis Res. Ther. 12, R33.
12. Germano, G., Frapolli, R., Simone, M., Tavecchio, M., Erba, E., Pesce, S., Pasqualini, F., Grosso, F., Sanfilippo, R., Casali, P.G., Gronchi, A., Virdis, E., Tarantino, E., Pilotti, S., Greco, A., Nebuloni, M., Galmarini, C.M., Tercero, J.C., Mantovani, A., D'Incalci, M., Allavena, P., Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 70, 2235-2244.
13. Hagimoto, N., Kuwano, K., Nomoto, Y., Kunitake, R., Hara, N., 1997. Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Cell Mol. Biol. 16, 91-101.
14. Li, W.W., Takahashi, N., Jhanwar, S., Cordon-Cardo, C., Elisseyeff, Y., Jimeno, J., Faircloth, G., Bertino, J.R., 2001. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin. Cancer Res. 7, 2908-2911.
15. Li, Y., Rory Goodwin, C., Sang, Y., Rosen, E.M., Laterra, J., Xia, S., 2009. Camptothecin and Fas receptor agonists synergistically induce medulloblastoma cell death: ROS-dependent mechanisms. Anticancer Drugs 20, 770-778.
16. Llado, V., Gutierrez, A., Martinez, J., Casas, J., Teres, S., Higuera, M., Galmes, A., Saus, C., Besalduch, J., Busquets, X., Escriba, P.V., 2008. Minerval Induces Apoptosis in Jurkat and Other Cancer Cells. J. Cell. Mol, Med.
17. Martinez, J., Gutierrez, A., Casas, J., Llado, V., Lopez-Bellan, A., Besalduch, J., Dopazo, A., Escriba, P.V., 2005. The repression of E2F-1 is critical for the activity of Minerval against cancer. J. Pharmacol. Exp. Ther. 315, 466-474.
18. Micheau, O., Thome, M., Schneider, P., Holler, N., Tschopp, J., Nicholson, D.W., Briand, C., Grutter, M.G., 2002. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J. Biol. Chem. 277, 45162-45171.
19. Minuzzo, M., Marchini, S., Broggini, M., Faircloth, G., D'Incalci, M., Mantovani, R., 2000. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc. Natl Acad. Sci. USA 97, 6780-6784.
20. Muller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S.L., Galle, P.R., Stremmel, W., Oren, M., Krammer, P.H., 1998. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188, 2033-2045.
21. Oh, H.Y., Namkoong, S., Lee, S.J., Por, E., Kim, C.K., Billiar, T.R., Han, J.A., Ha, K.S., Chung, H.T., Kwon, Y.G., Lee, H., Kim, Y.M., 2006. Dexamethasone protects primary cultured hepatocytes from death receptor-mediated apoptosis by upregulation of cFLIP. Cell Death Differ. 13, 512-523.
22. Panka, D.J., Mier, J.W., 2003. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J. Biol. Chem. 278, 37632-37636.
23. Panka, D.J.,Mano, T., Suhara, T., Walsh, K., Mier, J.W., 2001. Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J. Biol. Chem. 276, 6893-6896.
24. Safa, A.R., Day, T.W., Wu, C.H., 2008. Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr. Cancer Drug Targets 8, 37-46. (Pubitemid 351237908)
25. Soares, D.G., Escargueil, A.E., Poindessous, V., Sarasin, A., de Gramont, A., Bonatto, D., Henriques, J.A., Larsen, A.K., 2007. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc. Natl Acad. Sci. USA 104, 13062-13067.
26. Takebayashi, Y., Goldwasser, F., Urasaki, Y., Kohlhagen, G., Pommier, Y., 2001a. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin. Cancer Res. 7, 185-191.
27. Takebayashi, Y., Pourquier, P., Zimonjic, D.B.,Nakayama, K., Emmert, S., Ueda, T., Urasaki, Y., Kanzaki, A., Akiyama, S.I., Popescu, N., Kraemer, K.H., Pommier, Y., 2001b. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat. Med. 7, 961-966.
28. Tavecchio, M., Simone, M., Erba, E., Chiolo, I., Liberi, G., Foiani, M., D'Incalci, M., Damia, G., 2008. Role of homologous recombination in trabectedin-induced DNA damage. Eur. J. Cancer 44, 609-618.
29. Valoti, G., Nicoletti, M.I., Pellegrino, A., Jimeno, J., Hendriks, H., D'Incalci, M., Faircloth, G., Giavazzi, R., 1998. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin. Cancer Res. 4, 1977-1983.
30. Wen, L.P., Madani, K., Fahrni, J.A., Duncan, S.R., Rosen, G.D., 1997. Dexamethasone inhibits lung epithelial cell apoptosis induced by IFN-gamma and Fas. Am. J. Physiol. 273, L921-L929.
31. Wesselborg, S., Engels, I.H., Rossmann, E., Los, M., Schulze-Osthoff, K., 1999. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood 93, 3053-3063. (Pubitemid 29200798)
32. Wolf, B.B., Green, D.R., 1999. Suicidal tendencies: apoptotic cell death by caspase family proteinases. J. Biol. Chem. 274, 20049-20052.
33. Xia, S., Rosen, E.M., Laterra, J., 2005. Sensitization of glioma cells to Fas-dependent apoptosis by chemotherapy-induced oxidative stress. Cancer Res. 65, 5248-5255. (Pubitemid 40827335)
34. Zewail-Foote, M., Hurley, L.H., 1999. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J. Med. Chem. 42, 2493-2497.
35. Zhang, N., Hopkins, K., He, Y.W., 2008. c-FLIP protects mature T lymphocytes from TCR-mediated killing. J. Immunol. 181, 5368-5373.